Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States

IMPORTANCE: Clinical data on hepatitis C virus (HCV) treatment rates in the United States are sparse. OBJECTIVE: To evaluate HCV treatment rates in the era of direct-acting antivirals (DAAs). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the deidentified Optum Cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Vy H., Kam, Leslie, Yeo, Yee Hui, Huang, Daniel Q., Henry, Linda, Cheung, Ramsey, Nguyen, Mindie H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856330/
https://www.ncbi.nlm.nih.gov/pubmed/36477481
http://dx.doi.org/10.1001/jamanetworkopen.2022.45424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856330/
https://www.ncbi.nlm.nih.gov/pubmed/36477481
http://dx.doi.org/10.1001/jamanetworkopen.2022.45424

Ejemplares similares